Feedback received in the OMERACT community around the 3 projects is given in the sections below
Feedback received in the OMERACT community around the 3 projects is given in the sections below. Open in a separate window Figure 1 The OMERACT Filter 2.0 Instrument Selection Algorithm (OFISA) and red-amber-green checklist. OMERACT delegates endorsed the use of the PROMIS devices for fatigue, physical functioning, and pain interference (87.6% overall endorsement) and the disease-specific AAV-PRO instrument (89.4% overall endorsement). Conclusion The OMERACT Vasculitis Working Group gained endorsement by OMERACT for use of the PROMIS and the AAV-PRO in clinical trials of vasculitis. These devices are complementary to each other. The PROMIS and the AAV-PRO need further work to assess their power in longitudinal settings, including their ability to discriminate between treatments of varying efficacy in the setting of a randomized controlled trial. strong class="kwd-title" Key Indexing Terms: ANCA-ASSOCIATED…